首页> 外文OA文献 >PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia

【2h】

PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia

机译：在俄罗斯以贝伐单抗或西妥昔单抗为一线治疗的XELOX / FOLFOX4方案的mCRC治疗的PCN91药物经济学分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tikhomirova A.V.; Yagudina R.I.; Kulikov A.U.;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials [J] . Yingqian Lv, Zixin Yang, Li Zhao, International Journal of Clinical and Experimental Medicine . 2015,第1期

机译：在基于西妥昔单抗或帕尼单抗的治疗中添加贝伐单抗治疗转移性结直肠癌（mCRC）的有效性和安全性：一项来自随机对照试验的荟萃分析
2. 3012 ORAL Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results [J] . M.Rothenberg, M.Navarro, C.Butts, European Journal of Cancer Supplements . 2007,第4期

机译：3012年口服卡培他滨+奥沙利铂（XELOX）与5-FU / LV +奥沙利铂（FOLFOX4）作为转移性结直肠癌（MCRC）患者的二线治疗：III期试验结果
3. Effectiveness of I and II line chemo-targeted therapy according to the scheme Oxaliplatin Capecitabine Bevacizumab (XELOX BVZ) in patients with metastatic colorectal cancer (mCRC) [J] . Kaldigul Smagulova, Nino Chichua, Zhetkergen Arzykulov, Medical and Health Science Journal . 2011,第4期

机译：奥沙利铂卡培他滨贝伐单抗方案（XELOX BVZ）对转移性结直肠癌（mCRC）的I和II线化学靶向治疗的有效性
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. Alendronate and hormone replacement therapy in the prevention of osteoporotic fracture: A pharmacoeconomic analysis employing a net -benefit regression method of cost -effectiveness. [D] . Tiller, Kevin Wade. 2004

机译：阿仑膦酸盐和激素替代疗法在预防骨质疏松性骨折中的作用：药物经济学分析，采用成本效益的净效益回归方法。
6. The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials [O] . Yingqian Lv, Zixin Yang, Li Zhao, 2015

机译：在以西妥昔单抗或帕尼单抗为基础的治疗中添加贝伐单抗治疗转移性结直肠癌（mCRC）的有效性和安全性：一项来自随机对照试验的荟萃分析
7. PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT [O] . Tikhomirova A, Kulikov A, Yagudina R 2010

机译：用XOX或FOLFOX4联合或不联合贝伐单抗作为一线治疗的转移性大肠癌直接治疗的PCN87药物经济学分析

PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia

著录项

引文网络

相似文献

相关主题

期刊订阅